Evidence map›Paper›PMID 30186366›Full record

ArticleTherapeutic advances in urology2018

Reducing risk of

Ivy Y Ge, Helene B Fevrier, Carol Conell, Malika N Kheraj, Alexander C Flint, Darvin S Smith, Lisa J Herrinton

Open access · bronzeAbstract read
In one paragraph

Article in Therapeutic advances in urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Observational
  2. Observational
  3. TreatingACG case reports journal · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Antibiotic-Specific Risk for Community-AcquiredAntimicrobial agents and chemotherapy · 2022
    Article
  9. PeerJ · 2020
    Article
  10. Observational
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ivy Y GeInpatient Pharmacy, Kaiser Permanente Northern California South San Francisco Medical Center, 1200 El Camino Real, 3rd Floor, South San Francisco, CA 94080, USA.
Helene B FevrierDivision of Research, Kaiser Permanente, Oakland, CA, USA.
Carol ConellDivision of Research, Kaiser Permanente, Oakland, CA, USA.
Malika N KherajDepartment of Infectious Disease, Kaiser Permanente Redwood City Medical Center, Redwood City, CA, USA.
Alexander C FlintDepartment of Neurology, Kaiser Permanente Redwood City Medical Center, Redwood City, CA, USA.
Darvin S SmithDepartment of Infectious Disease, Kaiser Permanente Redwood City Medical Center, Redwood City, CA, USA.
Lisa J HerrintonDivision of Research, Kaiser Permanente, Oakland, CA, USA.ORCID https://orcid.org/0000-0002-5702-7162
Kaiser Permanente · USKaiser Permanente Redwood City Medical Center · USKaiser Permanente South San Francisco Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRisk of community-acquired

methodsWe conducted a nested case-control study at Kaiser Permanente Northern California, 2007-2010, to assess antibiotic prescribing and other factors in relation to risk of CA-CDI in outpatients with uncomplicated UTI. Cases were diagnosed with CA-CDI within 90 days of antibiotic use. We used matched controls and confirmed case-control eligibility through chart review. Antibiotics were classified as ciprofloxacin (most common), or low risk (nitrofurantoin, sulfamethoxazole/trimethoprim), moderate risk, or high risk (e.g. cefpodoxime, ceftriaxone, clindamycin) for CDI. We computed the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the relationship of antibiotic treatment for uncomplicated UTI and history of relevant gastrointestinal comorbidity (including gastrointestinal diagnoses, procedures, and gastric acid suppression treatment) with risk of CA-CDI using logistic regression analysis.

resultsDespite the large population, only 68 cases were confirmed with CA-CDI for comparison with 112 controls. Female sex [81% of controls, adjusted odds ratio (OR) 6.3, CI 1.7-24), past gastrointestinal comorbidity (prevalence 39%, OR 2.3, CI 1.1-4.8), and nongastrointestinal comorbidity (prevalence 6%, OR 2.8, CI 1.4-5.6) were associated with increased CA-CDI risk. Compared with low-risk antibiotic, the adjusted ORs for antibiotic groups were as follows: ciprofloxacin, 2.7 (CI 1.0-7.2); moderate-risk antibiotics, 3.6 (CI 1.2-11); and high-risk antibiotics, 11.2 (CI 2.4-52).

conclusionsLower-risk antibiotics should be used for UTI whenever possible, particularly in patients with a gastrointestinal comorbidity. However, UTI can be managed through alternative approaches. Research into the primary prevention of UTI is urgently needed.

Indexed as

antimicrobial stewardshipClostridium difficile infectioncommunity-based studiesoutpatient careurinary tract infection

Identifiers

PMID30186366
PMCPMC6120184
OpenAlexW2809379695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.